Biotech startups that raised Series C in Switzerland
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Cutiss | Zürich | Series C | $38.8M | 2025-09-10 |
| Numab | Wädenswil | Series C | $54.8M | 2025-01-09 |
| ImmunOs Therapeutics | Schlieren | Series C | $11.0M | 2024-09-17 |
| Asceneuron | Lausanne | Series C | $100.0M | 2024-07-16 |
| Bright Peak Therapeutics | Allschwil | Series C | $90.0M | 2024-06-11 |
| Memo Therapeutics | Schlieren | Series C | $22.0M | 2024-05-07 |
| Nanolive | Ecublens | Series C | $2.2M | 2022-09-20 |
| NBE-Therapeutics | Basel | Series C | $22.0M | 2020-01-10 |
8 rows of the CSV in 5 of its 18 columns.
- The 20 biotech startups in Switzerland whose last round is Series C have raised $1.1B in total.
- Novo Holdings is an investor in 3 of them, more than any other fund.
- Health care is the most common other sector, with 16 companies (80%).
- 0% were founded in 2020 or later; the median founding year is 2011.
- The most common team size is 11 to 50 employees (45% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
10 of 20| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Cutiss | Cutiss is a life science company that produces regenerative medicine and engineers skin tissue. | Biotech | Zürich | Series C | $38.8M | 2025-09-10 | $94.6M | Innosuisse | 11 to 50 | 2017 |
| ImmunOs Therapeutics | ImmunOs Therapeutics is a clinical-stage biotechnology company. | Biotech | Schlieren | Series C | $11.0M | 2024-09-17 | Lightspeed Venture Partners, Innosuisse, Mission BioCapital +1 | 11 to 50 | 2014 | |
| Asceneuron | Asceneuron develops therapeutics for orphan tauopathies and Alzheimer's disease. | Biotech | Lausanne | Series C | $100.0M | 2024-07-16 | OrbiMed, Novo Holdings, EQT Life Sciences +1 | 1 to 10 | 2012 | |
| Memo Therapeutics | Memo Therapeutics conducts biotechnology research in antibody discovery and immune repertoire analysis. | Biotech | Schlieren | Series C | $22.0M | 2024-05-07 | $108.8M | Verve Ventures, Kurma Partners, Pureos Bioventures +1 | 11 to 50 | 2012 |
| NBE-Therapeutics | NBE-Therapeutics develops oncology treatments for cancer patients. | Biotech | Basel | Series C | $22.0M | 2020-01-10 | $65.7M | Novo Holdings, Boehringer Ingelheim Venture Fund, PPF Group | 11 to 50 | 2012 |
| dacadoo | dacadoo offers digital lifestyle solutions through mobile apps from its base in Switzerland. | Biotech | Zürich | Series C | $71.1M | 2019-12-13 | Samsung Ventures | 51 to 100 | 2010 | |
| Andrew Alliance | Andrew Alliance is a Swiss pioneer in robotics for the life sciences sector. | Artificial intelligence | Geneva | Series C | $14.0M | 2018-06-12 | Venture Kick, Omega Funds, Rancilio Cube Sicaf | 11 to 50 | 2011 | |
| Endosense | Endosense develops medical technology that improves the reproducibility of catheter ablation for cardiac arrhythmias. | Biotech | Geneva | Series C | $41.2M | 2013-11-27 | 3i Group, VI Partners, Andera Partners +2 | 51 to 100 | 2003 | |
| Viroblock | Viroblock is a Swiss company developing antiviral technology for air filtration products. | Biotech | Geneva | Series C | $4.5M | 2012-02-14 | $4.5M | StartAngels Network, BlueOcean Ventures | 1 to 10 | 2005 |
| Synosia Therapeutics | Synosia Therapeutics develops and commercializes products for unmet needs in psychiatry and neurology. | Biotech | Basel | Series C | $30.0M | 2010-10-12 | $94.0M | Novo Holdings, Versant Ventures, 5AM Ventures +2 | 1 to 10 | 2006 |
Table 1. Biotech startups that raised Series C in Switzerland: the 10 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 20.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Novo Holdings | Corporate venture arm | Hellerup, Denmark | 3 | 15% | ||
| 2 | Innosuisse | Government investment office | Berne, Switzerland | 2 | 10% | ||
| 3 | BlackRock | Investment bank | New York, United States | 2 | 10% | ||
| 4 | Venture Kick | Startup incubator | Schlieren, Switzerland | 2 | 10% | ||
| 5 | StartAngels Network | Angel group | Zürich, Switzerland | 2 | 10% | ||
| 6 | BlueOcean Ventures | Venture capital firm | Plan-les-ouates, Switzerland | 2 | 10% | ||
| 7 | Cormorant Asset Management | Hedge fund | Boston, United States | 1 | 5% | ||
| 8 | Biotechnology Value Fund | Venture capital firm | San Francisco, United States | 1 | 5% | ||
| 9 | RTW Investments | Hedge fund | New York, United States | 1 | 5% | ||
| 10 | Mitsubishi UFJ Capital | Corporate venture arm | Tokyo, Japan | 1 | 5% | ||
| 11 | Mission BioCapital | Venture capital firm | Cambridge, United States | 1 | 5% | ||
| 12 | Lightspeed Venture Partners | Venture capital firm | Menlo Park, United States | 1 | 5% | ||
| 13 | Samsara BioCapital | Private equity firm | Palo Alto, United States | 1 | 5% | ||
| 14 | SR One | Venture capital firm | Cambridge, United States | 1 | 5% | ||
| 15 | EQT Life Sciences | Private equity firm | Amsterdam, The Netherlands | 1 | 5% |
Table 2. Biotech startups that raised Series C in Switzerland: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 16 | 80% | $1.1B |
| Software | 3 | 15% | |
| Hardware | 2 | 10% | |
| Fintech | 1 | 5% | |
| Artificial intelligence | 1 | 5% |
Table 3. Biotech startups that raised Series C in Switzerland by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series C | 20 | 100% | $25.9M |
Table 4. Biotech startups that raised Series C in Switzerland by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| Geneva | 4 | 20% |
| Schlieren | 3 | 15% |
| Zürich | 2 | 10% |
| Wädenswil | 2 | 10% |
| Basel | 2 | 10% |
| Lausanne | 1 | 5% |
| Allschwil | 1 | 5% |
| Cham | 1 | 5% |
| Ecublens | 1 | 5% |
| Epalinges | 1 | 5% |
| Plan-les-ouates | 1 | 5% |
| Landquart | 1 | 5% |
Table 5. Biotech startups that raised Series C in Switzerland by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2025 | 2 | 10% | $93.6M |
| 2024 | 4 | 20% | $223.0M |
| 2023 | 1 | 5% | $25.9M |
| 2022 | 1 | 5% | $2.2M |
| 2020 | 1 | 5% | $22.0M |
| 2019 | 2 | 10% | $79.1M |
Table 6. Biotech startups that raised Series C in Switzerland by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2015 to 2019 | 2 | 10% |
| 2010 to 2014 | 10 | 50% |
| Before 2010 | 8 | 40% |
Table 7. Biotech startups that raised Series C in Switzerland by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 6 | 30% |
| 11 to 50 | 9 | 45% |
| 51 to 100 | 4 | 20% |
| 101 to 250 | 1 | 5% |
Table 8. Biotech startups that raised Series C in Switzerland by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series C and its headquarters is in Switzerland. On 16 November 2026 that is 20 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 10 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 20 rows: 3 have no round amount, 0 no city and 7 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Switzerland whose last round is Series C are on the list?
- 20, in the file dated 16 November 2026.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 20 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.